Leadership & Pay ·
On July 3, 2026, Morana Jovan-Embiricos, Ph.D., resigned from the board of directors and the Audit Committee, stating…
KLRSKalaris Therapeutics, Inc.
On July 3, 2026, Morana Jovan-Embiricos, Ph.D., resigned from the board of directors and the Audit Committee, stating the decision was unrelated to any disagreement with company operations. On the same day, the board elected Laurie Keating to serve as a Class I director and member of the Audit Committee, effective August 1, 2026. Ms. Keating will receive $40,000 in annual cash board compensation, $7,500 for Audit Committee service, and an option to purchase 18,000 shares of common stock vesting monthly over three years. Kalaris Therapeutics, Inc. is a biotechnology company that develops therapeutic treatments.